Bolt Clinical Development
Bolt Biotherapeutics
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Bolt Clinical Development as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:52 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06921837 · A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal CancerBolt Biotherapeutics, Inc. · recruiting · Gastric Cancer Adenocarcinoma Metastatic, Gastroesophageal Adenocarcinoma · study director
- Ph1NCT06052852 · Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced MalignanciesBolt Biotherapeutics, Inc. · terminated · Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer · study director
- Ph2NCT05954143 · Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast CancerBolt Biotherapeutics, Inc. · terminated · Metastatic Breast Cancer, HER2-positive Breast Cancer · study director
- Ph1/Ph2NCT04278144 · A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid TumorsBolt Biotherapeutics, Inc. · terminated · HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.